Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?
Executive Summary
The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.
You may also be interested in...
EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.
In US Drug Pricing Debate, ICER’s Voice Gets Louder
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
The IPO Party Is Over – How Bad Is The Hangover?
Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?